DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
DaVita HealthCare (DVA) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 12.22% and 1%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights DaVita, RadNet and U.S. Physical Therapy
by Zacks Equity Research
DaVita, RadNet and U.S. Physical Therapy are included in this blog.
3 Stocks to Bank on the Buoyant Outpatient Home Health Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, RDNT and USPH are well-poised to gain from the prospects.
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Sustained momentum with respect to inpatient dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the fourth quarter despite the ongoing pandemic-led business challenges.
DaVita HealthCare (DVA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DaVita's (DVA) Collaboration to Aid in Kidney Care Needs
by Zacks Equity Research
DaVita's (DVA) work with transplant providers and kidney doctors is likely to slow CKD progression and bolster access to home dialysis and kidney transplantation.
DaVita's (DVA) New Buyout to Enhance Transplant Experience
by Zacks Equity Research
DaVita (DVA) acquires MedSleuth which will help simplify the kidney transplant process and provide patients greater access to transplantation.
Forget DaVita (DVA), Buy These 3 Lucrative Medical Care Stocks
by Trina Mukherjee
With stocks offering dialysis services, including DaVita (DVA), facing several issues, it would be prudent to invest in medical care and services stocks like DGX, AMN and CODX instead for 2022.
New Strong Sell Stocks for December 28th
by Zacks Equity Research
DVA, CSII, BYND, AVYA, and GFF have been added to the Zacks Rank #5 (Strong Sell) List on December 28, 2021.
DaVita (DVA) Study Favors mRNA Vaccines for Dialysis Patients
by Zacks Equity Research
DaVita's (DVA) latest study indicates favorable outcomes for ESKD patients regarding the COVID-19 vaccines.
New Strong Sell Stocks for November 29th
by Zacks Equity Research
DVA, NVST, WWD, PHR, and ROAD have been added to the Zacks Rank #5 (Strong Sell) List on November 29, 2021
New Strong Sell Stocks for November 19th
by Zacks Equity Research
AMED, CSII, DVA, GFF, and LTRX have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2021.
New Strong Sell Stocks for November 3rd
by Zacks Equity Research
TEAM, DVA, FLS, JD, and SBUX have been added to the Zacks Rank #5 (Strong Sell) List on November 3, 2021.
DaVita (DVA) Beats on Q3 Earnings, Narrows 2021 EPS View
by Zacks Equity Research
DaVita's (DVA) strength in dialysis patient service revenues drives its Q3 top line.
New Strong Sell Stocks for October 29th
by Zacks Equity Research
IBIO, POST, INSM, DVA, and BSET have been added to the Zacks Rank #5 (Strong Sell) List on October 29, 2021.
DaVita HealthCare (DVA) Q3 Earnings Top Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 6.79% and -0.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the third quarter despite the ongoing pandemic-led business challenges.
DaVita HealthCare (DVA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold Onto Select Medical (SEM) Now
by Zacks Equity Research
Select Medical (SEM) is a long-term player on the back of its leadership position in acute care services.
Why Is DaVita HealthCare (DVA) Down 2.3% Since Last Earnings Report?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Encompass Health's (EHC) Growth View Makes It a Good Buy
by Sapna Bagaria
Ageing population, building of hospitals and other operational efforts poise Encompass Health (EHC) well for long-term growth, thus making it a good investment option.
7 Reasons Why Select Medical (SEM) Stock Looks Attractive
by Zacks Equity Research
Select Medical (SEM) looks a profitable investment bet on the back of its top-line growth, backed by a solid financial position as well as acquisitions and joint ventures.
Are Investors Undervaluing DaVita HealthCare (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita (DVA) Beats on Q2 Earnings, Raises 2021 EPS View
by Zacks Equity Research
DaVita's (DVA) strength in dialysis patient service revenues drives its Q2 top line.
DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 23.36% and 1.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?